Ahmedabad (Gujarat) [India] November 14: Lincoln Pharmaceuticals Limited, one of India’s leading healthcare companies has reported standalone net profit of Rs. 50.03 crore for the half year ended 30th September 2024, growth of 7.55% Y-O-Y as compared to the net profit of Rs. 46.52 crore in H1 FY24. Income from operation for the H1 FY25 […]
Continue Reading
Mr. Mahendra Patel, MD, Lincoln Pharmaceuticals Ltd Company in the elite club of just 16 companies out of 4,200 plus companies listed on the Indian Stock Exchange to do so Ahmedabad (Gujarat) [India], July 31: Lincoln Pharmaceuticals Limited, one of India’s leading healthcare companies, has achieved the milestone of reporting a profit growth every single […]
Continue Reading
Mr. Mahendra Patel, MD, Lincoln Pharmaceuticals Ltd FY23 Results Highlights:– (Standalone) · Net Profit Reports Y-o-Y growth of 5.11% to Rs. 72.90 crore; · Total Income reports Y-o-Y growth of 10.52% to Rs. 532.79 crore; · EBITDA reports Y-o-Y growth of 5.86% to Rs. 111.65 crore. · Company recommends 15% dividend, Rs. 1.5 per share for FY 23 Q4FY23 Results Highlights:– (Standalone) · Net Profit Reports Y-o-Y […]
Continue Reading
Stock price gained over 15% in a week; Touched an All-time-High of Rs. 451 per share on 18 May 2023 Ahmedabad (Gujarat) [India], May 20: The share price of Ahmedabad-based leading pharmaceutical company – Lincoln Pharmaceuticals Ltd made an all-time high. The share price of the company has gained more than 15% in a week […]
Continue Reading
Mr . Mahendra Patel, Managing Director, Lincoln Pharmaceuticals Ltd Highlights:- · Total Income from operation in Q2 FY23 at ₹ 146.30 crore, up 12.5% from ₹ 130.00 crore in Q1 FY23; · During the year, company got an approval from WHO-GMP for Tablet Capsule, dry-powder Suspension products at Cephalosporin plant. · Approved dividend of ₹ […]
Continue Reading
Mr. Mahendra Patel, MD, Lincoln Pharmaceuticals Ltd Business Highlights:– Total Income in Q1FY23 at Rs. 129.97 crore, up 24.4% from Rs. 104.4 crore in Q4FY22 Commercial operations of Cephalosporin Plant and Export to EU & Australia to commence in FY23 Company continuous to remain ‘Net Debt Free’ after multiple expansion & acquisition of Cephalosporin plant […]
Continue Reading